Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation
- 1 November 2013
- journal article
- Published by Elsevier BV in Colloids and Surfaces B: Biointerfaces
- Vol. 111, 346-353
- https://doi.org/10.1016/j.colsurfb.2013.06.001
Abstract
No abstract availableFunding Information
- Department of Biotechnology, Government of India
This publication has 22 references indexed in Scilit:
- The emerging role of P-glycoprotein inhibitors in drug delivery: a patent reviewExpert Opinion on Therapeutic Patents, 2011
- Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulationDrug Discovery Today, 2009
- Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistanceJournal of Controlled Release, 2009
- Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer ChemotherapyJournal of Pharmacy & Pharmaceutical Sciences, 2009
- Natural and Synthetic Polymers as Inhibitors of Drug Efflux PumpsPharmaceutical Research, 2007
- Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new Polymer-Lipid Hybrid Nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancerJournal of Controlled Release, 2006
- Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticlesBiomaterials, 2000
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugsCell, 1994
- Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.Journal of Histochemistry & Cytochemistry, 1990
- Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proceedings of the National Academy of Sciences of the United States of America, 1987